FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Feb 27, 2026
Azitra, Inc. (AZTR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $11.0 million. Free cash flow was -$11.2 million. As of Jun 30, 2026 it held $6.7 million in cash and investments and $410,053 in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-10.96M
-22.2% vs prior year
Operating cash flow (TTM)
$-11.11M
-1.4% vs year-ago TTM
Free cash flow (TTM)
$-11.17M
-1.9% vs year-ago TTM
EPS
$-2.25
+85.7% vs prior year
Dividend per share
None
Shares outstanding
16.19M
+8.1% vs prior year
Net cash
$6.32M
as of Jun 30, 2026
Operating margin
-146468.5%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZTR (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Branford, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1701478
- Former names
- Azitra Inc (until Jan 4, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $7,500 | $686,000 |
| Operating income | -$11.0M | -$11.0M | -$7.5M |
| Net income | -$11.0M | -$9.0M | -$11.3M |
| Diluted EPS | -$2.25 | -$15.70 | -$54.98 |
| Operating cash flow | -$11.2M | -$10.2M | -$7.4M |
| Free cash flow | -$11.2M | -$10.2M | -$7.4M |
| Total assets | $5.0M | $7.4M | $5.1M |
| Total liabilities | $1.2M | $1.7M | $2.2M |
| Stockholders' equity | $3.8M | $5.7M | $2.9M |
| Cash and investments | $2.1M | $4.6M | $1.8M |
| Total debt | $422,077 | $555,508 | $885,947 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
All 237 Azitra, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.